
































**National Association of State Controlled  
Substances Authorities**

**Drug Abuse Trends Survey  
September 2016**

## 1. In what state do you work?




Value	Percent	Count
Alabama	6.1%	2
Alaska	0.0%	0
Arizona	0.0%	0
Arkansas	0.0%	0
California	3.0%	1
Colorado	0.0%	0
Connecticut	3.0%	1
Delaware	0.0%	0
District of Columbia	0.0%	0
Florida	0.0%	0
Georgia	0.0%	0
Guam	3.0%	1
Hawaii	0.0%	0
Idaho	3.0%	1
Illinois	0.0%	0
Indiana	3.0%	1
Iowa	3.0%	1
Kansas	3.0%	1
Kentucky	3.0%	1
Total		33

Value	Percent		Count
Louisiana	0.0%		0
Maine	6.1%		2
Maryland	0.0%		0
Massachusetts	0.0%		0
Michigan	3.0%		1
Minnesota	3.0%		1
Mississippi	3.0%		1
Missouri	3.0%		1
Montana	3.0%		1
Nebraska	0.0%		0
Nevada	6.1%		2
New Hampshire	3.0%		1
New Jersey	0.0%		0
New Mexico	6.1%		2
New York	0.0%		0
North Carolina	0.0%		0
North Dakota	3.0%		1
Ohio	0.0%		0
Oklahoma	3.0%		1
Oregon	3.0%		1
Pennsylvania	3.0%		1
Rhode Island	0.0%		0
South Carolina	6.1%		2
South Dakota	3.0%		1
Tennessee	3.0%		1
Texas	6.1%		2
Utah	0.0%		0
Vermont	0.0%		0
Virginia	0.0%		0
Washington	0.0%		0
		Total	33


Value	Percent	Count
West Virginia	3.0%	1
Wisconsin	0.0%	0
Wyoming	0.0%	0
Total		33

2. Do you consider the abuse of promethazine in combination with codeine, other opioids or drugs to be a significant issue in your state?



Value	Percent	Count
Yes	58.1%	18
No	41.9%	13
Total		31

3. Is your state experiencing any signs/trends of increasing abuse or diversion of promethazine in combination with codeine, other opioids or drugs and how would you characterize the scope the problem?




Value	Percent	Count
Significant increase	32.3%	10
Minimal increase	22.6%	7
No noticeable increase	45.2%	14
Total		31

## Comments

Count	Response
1	Going on for the past 10 years
1	I am unaware of any issues with promethazine abuse
1	Primarily in the West Tennessee area
1	Weekly the NV PMP receives notification of fraudulent promethazine w/ codeine prescriptions
1	We began tracking tramadol after it was classified as a controlled substance and tramadol use ranks within the top 5 prescribed controlled substances in Iowa. Although the recent tracking of tramadol has changed the ranking of top prescribed controlled substances, use of the remaining top controlled substances has not changed appreciably.
1	We are experiencing trafficking from other cities especially in the I-75 corridor, along with fraudulent prescriptions.
1	The only way I would be aware of an increase would be through unsolicited comments during pharmacy inspections and I have heard none.
1	Over the past 3 quarters there has been an increase in promethazine with codeine prescribed that appears to be more than just due to the normal increase there would be for winter. The DEA and CME offices have no reports of diversion or OD from this.

4. Has your state taken any measures to address the abuse or diversion of this product?




Value	Percent	Count
No	54.6%	18
Considering rescheduling	9.1%	3
Monitoring drugs via the prescription monitoring program	30.3%	10
Other	24.2%	8
Total		33

Responses "Other"	Count
Left Blank	25
Cough syrups containing codeine are schedule 3 in MN	1
I am unaware of any measures taken to address promethazine abuse	1
None by the Board of Pharmacy	1
Pharmacy awareness	1
Pursuing enhanced licensing sanctions for over prescribers and over dispensers of this product.	1
Sending alerts to KY pharmacists regarding fraudulent schemes.	1
State inspectors are working these cases	1
NV PMP has been working with law enforcement to identify those who are writing fraudulent prescriptions for promethazine w/codeine.	1




5. Do you consider the abuse of gabapentin to be a significant issue in your state?



Value	Percent	Count
Yes	30.0%	9
No	70.0%	21
Total		30

6. Is your state experiencing any signs/trends of increasing abuse or diversion of gabapentin and how would you characterize the scope of the problem?




Value	Percent		Count
Significant increase	19.4%		6
minimal increase	25.8%		8
No noticable increase	54.8%		17
		Total	31

## Comments

<b>Count</b>	<b>Response</b>
1	A study has not been conducted to make this determination. Same applies to Q#1.
1	Gabapentin is showing up in about 40% of KY drug overdoses. Not the cause of death, but present.
1	Have seen this increase primarily in proximity to our reservations
1	Marked increase in the involvement with drug overdose deaths
1	Indiana recorded 76 doses dispensed in January 2016 and so far September 2016 we have recorded 2,437. We do not have enough data to establish a baseline to determine if there is a problem or how significant it may be
1	With the scheduling of Carisoprodol to a scheduled drug, Gabepentin appears to have taken its place.


7. Has your state taken any measures to address the abuse or diversion of gabapentin?



Value	Percent	Count
No	81.8%	27
Considering rescheduling	12.1%	4
Monitoring the drug via the prescription monitoring program	6.1%	2
Other	3.0%	1
Total		33


Responses "Other"	Count
Left Blank	32
A study has not been conducted to make this determination.	1

8. Do you consider the abuse of loperamine to be a significant issue in your state?



Value	Percent	Count
Yes	3.3%	1
No	96.7%	29
Total		30

9. Is your state experiencing any signs/trends of increasing abuse or diversion involving loperamide and how would you characterize the scope of the problem?




Value	Percent	Count
Significant increase	3.3%	1
Minimal increase	10.0%	3
No noticeable increase	86.7%	26
Total		30

## Comments

Count	Response
1	A study has not been conducted to make this determination. This applies to Q8 as well.
1	I am unaware of any issues with loperamine abuse
1	We only can track controlled substances, and we are not aware of issues with loperamine

10. Has your state taken any measures to address the abuse or diversion of loperamide?




Value	Percent	Count
No	90.9%	30
Considering rescheduling	0.0%	0
Monitoring via the prescription monitoring program	3.0%	1
Requiring pharmacies to place drug behind the counter	0.0%	0
Other	6.1%	2
Total		33

Responses "Other"	Count
Left Blank	31
A study has not been conducted to make this determination.	1
I am unaware of any measures taken to address loperamine abuse	1




11. What other drugs/chemicals have shown increasing signs/trends of abuse or diversion in your state)?



Value	Percent	Count
None	12.9%	4
Synthetic marijuana	35.5%	11
Bath salts/incense	41.9%	13
Fentanyl (synthetic)	64.5%	20
Fentanyl (pharmaceutical)	25.8%	8
Molly (MDMA)	9.7%	3
Other drugs	16.1%	5
Total		31

Responses "Other drugs"	Count
Left Blank	28
A study has not been conducted to make this determination.	1
Heroin	1
ICE	1
Kratom	1
methamphetamine, PCP, use of methylone to replace MDMA. Meth is huge and the MSM and HIV rates are back to 1998 levels.	1

12. In your state are pharmacists permitted to "administer" controlled substances by injection?




Value	Percent	Count
Yes	35.7%	10
No	64.3%	18
Total		28

## Comments

Count	Response
1	Ask Karen Tannert
1	administer or dispense ?
1	Pursuant to a specific prescription for a specific patient if the prescriber authorizes or directs pharmacist administration.
1	Under collaborative practice agreement within scope of practice and a clinical licensed practitioner endorsement of the pharmacist
1	32 MRS §13702, 28. Practice of pharmacy. "Practice of pharmacy" means the interpretation and evaluation of prescription drug orders; the compounding, dispensing and labeling of drugs and devices, except labeling by a manufacturer, packer or distributor of nonprescription drugs and commercially packaged legend drugs and devices; the participation in drug selection and drug utilization reviews; the proper and safe storage of drugs and devices and the maintenance of proper records for these drugs and devices; the administration of vaccines licensed by the United States Food and Drug Administration that are recommended by the United States Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, or successor organization, for administration to adults; the performance of collaborative drug therapy management; the responsibility for advising, when necessary or regulated, of therapeutic values, content, hazards and use of drugs and devices; and the offering or performing of those acts, services, operations or transactions necessary in the conduct, operation, management and control of a pharmacy.

13. in your state are there currently any legislative, regulatory or other initiatives underway which would, in the future, permit pharmacists to administer controlled substances by injection?



Value	Percent	Count
Yes	3.9%	1
No	96.2%	25
Total		26

## Comments

Count	Response
1	Ask Tannert
1	I am unaware of any measures regarding this topic.
1	Since this is currently allowed, nothing needs to be changed.
1	32 MRS §13841 1. Engage in collaborative drug therapy management. A pharmacist licensed in this State who meets the qualifications and requirements of section 13842 and rules adopted by the board may engage in collaborative drug therapy management pursuant to a collaborative practice agreement with a practitioner. [ 2013, c. 308, §4 (NEW) .] 2. Scope of authority. A pharmacist engaging in collaborative drug therapy management pursuant to subsection 1 is entitled to adequate access to a patient's history, disease status, drug therapy and laboratory and procedure results and may: A. Collect and review a patient's history; [2013, c. 308, §4 (NEW).] B. Obtain and check vital signs; [2013, c. 308, §4 (NEW).] C. Order and evaluate the results of laboratory tests directly related to drug therapy under the supervision of, or in direct consultation with, a practitioner and in accordance with approved protocols applicable to the practice setting and when the evaluation does not include a diagnostic component; and [2013, c. 308, §4 (NEW).] D. Initiate, monitor, modify and discontinue drug therapy for a particular patient pursuant to the collaborative practice agreement with a practitioner who is treating the patient, as long as the action is reported to the practitioner in a timely manner as determined by rules adopted pursuant to section 13846.